Want to know what's happening next in healthcare?

MedCityNews is the leading online news source for the business of innovation in healthcare.


“I read MedCity because it captures the pulse of what's going on in healthcare innovation, a go to source. I also like how MedCity supports women in digital health.”

Dr. Charlene Ngamwajasat, @doctorcharlene, Physician and techie


Sign up for our daily newsletter


UK cost agency says ‘no’ to Celgene bone marrow drug

July 12, 2013 12:21 pm by | 0 Comments

LONDON (Reuters) - Celgene's drug Revlimid is not worth using on Britain's state health service because of uncertainty over whether it can extend the lives of patients with serious bone marrow disorders, the country's cost agency said on Thursday.

The draft guidance from the National Institute for Health and Clinical Excellence (NICE), if confirmed following a consultation process, would remove a treatment option for patients with myelodysplastic syndromes, which can lead to life-threatening diseases such as leukemia.

(Reporting by Ben Hirschler; Editing by Louise Heavens)

Copyright 2014 MedCity News. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
0 comments